newsfilter
← Latest News
GlobeNewswire·

CVRx to Participate at the Piper Sandler 37th Annual Healthcare Conference

  • CVRx management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, Dec. 3, 2025.
  • The event is scheduled for 2:00 p.m. ET & will be webcast live.
  • A live audio webcast will be available at ir.cvrx.com.
  • CVRx is a commercial-stage medical device company focused on neuromodulation solutions for cardiovascular diseases.
  • Barostim is the first FDA-approved neuromodulation technology to improve symptoms of heart failure.
  • Barostim delivers electrical pulses to carotid artery baroreceptors to restore autonomic nervous system balance.
  • Barostim holds FDA Breakthrough Device designation & is approved for heart failure in the U.S.
  • Barostim has EU MDR compliance & CE Mark approval for heart failure & resistant hypertension in the European Economic Area.